A randomized, open-label, multicenter study to evaluate the effect of Xolair (omalizumab) as add-on therapy to inhaled corticosteroid + long-acting beta agonist in fixed or flexible dosing compared to isolated inhaled corticosteroid + long-acting beta agonist in fixed or flexible dosing in the asthma-related quality of life in patients with severe persistent allergic asthma.

Trial Profile

A randomized, open-label, multicenter study to evaluate the effect of Xolair (omalizumab) as add-on therapy to inhaled corticosteroid + long-acting beta agonist in fixed or flexible dosing compared to isolated inhaled corticosteroid + long-acting beta agonist in fixed or flexible dosing in the asthma-related quality of life in patients with severe persistent allergic asthma.

Completed
Phase of Trial: Phase IV

Latest Information Update: 09 Mar 2016

At a glance

  • Drugs Beta-adrenergic receptor agonists; Corticosteroids; Omalizumab
  • Indications Allergic asthma
  • Focus Therapeutic Use
  • Sponsors Novartis
  • Most Recent Events

    • 20 May 2011 Status changed from active, no longer recruiting to completed as reported by ClinicalTrials.gov.
    • 19 Feb 2010 Patient numbers amended from 117 to 116 as reported by ClinicalTrials.gov.
    • 19 Feb 2010 Planned end date changed from 1 Apr 2009 to 1 Apr 2010 as reported by ClinicalTrials.gov.
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top